神经退行与大脑铁积累的神经退行
David A Schipper1, Hyman M Schipper2
1New York Medical College, Valhalla, NY, USA.
Advances in experimental medicine and biology
|July 2, 2025
概括
神经退行与大脑铁积累 (NBIA) 障碍涉及中枢神经系统 (CNS) 的病态铁积累. 本综述详细介绍了十种NBIA疾病,重点关注临床特征,神经成像和诊断策略.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 神经学 神经学
背景情况:
- 铁对神经发育至关重要,但如果失调,可能会产生神经毒性.
- 遗传性疾病可能会破坏铁的平衡,导致中枢神经系统内有病态的铁沉积.
- 脑铁积累的神经退行症 (NBIA) 涵盖了脑铁过多的特征.
研究的目的:
- 为了回顾十个不同的NBIA疾病.
- 为了强调临床表现和神经成像发现.
- 讨论差异诊断和铁化疗法.
主要方法:
- 十种NBIA疾病的综述,包括泛酸酶2相关的神经退行 (PKAN),神经皮性病,青素血症,库福-拉克布病 (KRD),PLA2G6相关的神经退行 (PLAN),FA2H相关的神经退行 (FAHN),伍德豪斯-萨卡蒂综合征 (WSS),β-螺旋蛋白相关的神经退行 (BPAN),线粒体膜蛋白相关的神经退行 (MPAN) 和协酶阿酶蛋白相关的神经退行 (CoPAN).
- 专注于临床综合征和神经成像,特别是对铁敏感的磁共振扫描序列.
- 探索诊断方法和当前的治疗策略,包括铁化.
主要成果:
- 提供了十种NBIA疾病的详细描述.
- 神经成像,特别是MRI,对于识别病态铁积累至关重要.
- 临床异质性存在于NBIA条件的全谱中.
结论:
- NBIA 疾病代表了一组与铁失调相关的复杂神经退行性疾病.
- 准确的诊断依赖于整合临床,遗传和神经成像数据.
- 对于特定的NBIA实体,正在研究治疗干预措施,包括铁化.
更多相关视频
09:21Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
Published on: February 23, 2024
1.0K
07:22Assessment of Blood-brain Barrier Permeability by Intravenous Infusion of FITC-labeled Albumin in a Mouse Model of Neurodegenerative Disease
Published on: November 8, 2017
10.2K
相关概念视频
01:37Neural Regulation
40.3K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.3K
01:26Alzheimer's Disease: Overview
678
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
678
00:49The Blood-brain Barrier
48.9K
Overview
48.9K
01:16Necrosis
4.9K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.9K
01:15Parkinson's Disease: Overview
718
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
718
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265